{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:22:21Z","timestamp":1789017741836,"version":"build-2803163510"},"reference-count":0,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,1,1]]},"DOI":"10.1182\/blood-2002-04-1258","type":"journal-article","created":{"date-parts":[[2002,12,16]],"date-time":"2002-12-16T21:02:38Z","timestamp":1040072558000},"page":"6-14","source":"Crossref","is-referenced-by-count":465,"title":["Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)"],"prefix":"10.1182","volume":"101","author":[{"given":"J. C.","family":"Byrd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2002,7,5]]},"container-title":["Blood"],"original-title":[],"deposited":{"date-parts":[[2011,8,22]],"date-time":"2011-08-22T14:42:15Z","timestamp":1314024135000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.bloodjournal.org\/cgi\/doi\/10.1182\/blood-2002-04-1258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,5]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-04-1258","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,5]]}}}